



Synthesis, Characterization and Biological studies of Novel Heterocyclic compounds

Shah H. J.*¹ and Chaudhari J. A.²

¹K.K. Shah Jarodwala Maninagar Science College, Ahmedabad, Gujarat, INDIA

²Shri R K Parikh Arts and Science College, Petlad, Gujarat, INDIA

Available online at: www.isca.in, www.isca.me

Received 30th Novmeber 2014, revised 29th Janaury2015, accepted 20th February 2015

Abstract

Reaction of *N*-((1*H*-benzoimidazol-2-yl)methyl)-*N*-methylethanamine(1) with chloro acetic acid and hydrazine hydrate gives 2-(2-((ethyl(methyl)amino)methyl)-1*H*-benzoimidazol-1-yl)acetohydrazide(2), Which react with CS₂/KOH gives 5-((2-((ethylmethylamino)methyl)-1*H*-benzoimidazol-1-yl)methyl)-1,3,4-oxadiazole-2(3*H*)-thione(3). The product (3) on Mannich reaction gives different 3-((dialkyl amino)methyl)-5-((2-((ethyl (methyl)amino)methyl)-1*H*-benzoimidazol-1-yl)methyl)-1,3,4-oxadiazole-2(3*H*)-thione (4a-e). The structures of these newly synthesized compounds were established on the basis of analytical studies as well as spectral studies. The final products were examined for their antibacterial studies and antifungal studies.

Keywords: Oxadiazole, benzimidazole, Mannich reaction, spectral studies, antibacterial and antifungal Activities.

Introduction

In recent time, the research done on hydrazide and its derivatives, because of their heterocyclic products show medicinal properties like, analgesic, anti-inflammatory, antibacterial, antifungal properties¹⁻³. The heterocyclic compounds containing nitrogen and oxygen atom are an important class of compounds⁴⁻⁶. Some of the compounds like, Oxadiazole and their derivatives play a significant role in medicinal chemistry⁷⁻¹⁰. Oxadiazole is 5 member heterocyclic compound having 2 nitrogen atoms and 1 oxygen atom. 1,3,4-oxadiazole and their substituted derivative have been found to exhibit diverse biological activities like, anticancer, antifungal, antibacterial, antioxidant, analgesic and anti-inflammatory¹¹⁻¹⁸. Oxadiazole work as bioisosteres of carbonyls and thioguanidines in H3 antagonists¹⁹⁻²⁰. In continuation of our earlier work²¹⁻²². It is thought to fuse both, Benzimidazole and oxadiazole compound which may increase the drug potency to some extent or they might exhibit some of the above mentioned biological activities. From this hope, the objective of the current research work is to synthesize new derivatives of oxadiazole containing Benzimidazole moiety. Hence the current work covers the synthesis of 3-((dialkylamino)methyl)-5-((2-((ethyl(methyl)amino)methyl)-1*H*-benzoimidazol-1-yl)methyl)-1,3,4-oxadiazole-2(3*H*)-thione (4a-e). The route of synthesis is shown in scheme-1.

Material and Methods


N-((1*H*-benzoimidazol-2-yl) methyl)-*N*-methylethanamine (1) was prepared by method shown in²³. All other chemicals were used of analytical grade. In open capillary tube, Melting points were determined and were uncorrected. The Infra Red spectra

were studied in potassium bromide pellets on a Nicolet 400D spectrometer and PMR spectra were studied in DMSO with TMS as internal standard on a Bruker spectrometer at 400 MHz. Antimicrobial activities of all compounds were examined against common bio species by using cup plate method.



Preparation of *N*-((1*H*-benzoimidazol-2-yl)methyl)-*N*-methylethanamine (1): 2-(chloromethyl)-1*H*-benzoimidazole (0.01 mole) was added to the mixture of the methyl ethyl amine (0.01mole) and anhy. K₂CO₃ (0.05 mole) in ethyl methyl ketone (15 ml). At ambient temperature the whole reaction mixture was stirred for 7- 8.5 hrs and ethyl methyl ketone was then evaporated. After addition of Distilled water to the residue, precipitate formed. This precipitate was filtered, washed with water and after removal of excess solvent, the product crystallized from CH₃OH. Yield is about 72%, M.P.171°C. Infra Red spectra cm⁻¹: 3150(NH) 1620-1648(C=N), 3020-3080(C-H,of Ar.), 2950, 2885, 1370(-CH₃,CH₂). PMR: 7.24-7.65 (multiplet,4H,Ar-H), 5.40(singlet,1H,NH), 4.46(singlet,2H,CH₂), 2.66(quartet,2H, CH₂), 1.12(triplet,3H,CH₃), 2.28 (singlet,3H,CH₃). Analysis Calculated for C₁₁H₁₅N₃ (189gm/mole): C, 69.81; H, 7.99; N, 22.20. Found: C, 69.79; H, 7.96; N, 22.18.

Preparation of 2-(2-((ethyl(methyl)amino)methyl)-1*H*-benzoimidazol-1-yl)acetohydrazide(2): A solution of *N*-((1*H*-benzoimidazol-2-yl) methyl)-*N*-methylethanamine (1) (0.01mole) in dry CH₃COCH₃ (60 ml) and ethylchloroacetate (0.01 mole) in the presence of anhy.K₂CO₃ (5 g) was refluxed for 9-9.5 hrs., after cooling the solid was filtered, dried and crystallized from C₂H₅OH, yield is 69%. M.P. 167°C. This compound (0.05mole) with hydrazine hydrate (0.05mole) and 1,4-dioxane (35 ml) was refluxed for 5 hrs. On heating coil .After removal of excess solvent, the product was crystallized from CH₃OH to give (2),



yield is 73%, M.P 182°C. Infra Red spectra cm^{-1} : 3350(NH_2), 1620-1648 ($\text{C}=\text{N}$), 3020-3080 ($\text{C}-\text{H}$, of Ar.), 2950, 2885, 1370($-\text{CH}_3, \text{CH}_2$), 1660-1670 ($-\text{CONH}$). PMR : 7.24–7.65(multiplet, 4H, Ar-H), 4.86-4.38(singlet, 4H, CH_2), 2.66 (quartet, 2H, CH_2), 1.12 (triplet, 3H, CH_3), 2.28 (singlet, 3H, CH_3), 7.8 (singlet, 1H, CONH), 4.6(singlet, 2H, NH_2). Analysis. Calculated for $\text{C}_{13}\text{H}_{19}\text{N}_5\text{O}$ (261): C, 59.75; H, 7.33; N, 26.80. Found: C, 59.73; H, 7.30; N, 26.78.





N-((1H-benzoimidazol-2-yl)methyl)-N-methylethanamine (1)



2-(2-((ethyl(methyl)amino)methyl)-1H-benzoimidazol-1-yl)acetohydrazide (2)



5-((2-((ethyl(methyl)amino)methyl)-1H-benzoimidazol-1-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione(3)



3-((dialkylamino)methyl)-5-((2-((ethyl(methyl)amino)methyl)-1H-benzoimidazol-1-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione (4a-e)

	4a	4b	4c	4d	4e
R	CH_3	CH_3	C_2H_5	C_2H_5	C_6H_5
R1	CH_3	C_2H_5	C_2H_5	C_6H_5	C_6H_5

Scheme-1

Preparation of 5-((2-((ethylmethylamino)methyl)-1H-benzimidazol-1-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione(3): To a cold stirred solution of 2-(2-((ethyl (methyl) amino) methyl)-1H-benzimidazol-1-yl) acetohydrazide (2) (0.01mole) in C₂H₅OH (50 ml) containing KOH (0.01mole) and CS₂ (0.05mole) was added gradually. The reaction mixture was heated on a steam-bath under reflux until H₂S evolution ceased. C₂H₅OH was removed under reduced pressure by distillation and the residue was stirred with distilled water, after filtration the filtrate was neutralized with dil.HCl. The product after filtration, washed with water and recrystallized from C₂H₅OH to get the compound 5-((2-((ethylmethylamino)methyl)-1H-benzimidazol-1-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione(3), which were obtained in 66% yield. Infra Red spectra cm⁻¹: 1620-1648(C=N), 3020-3080 cm⁻¹(C-H, of Ar.), 2950, 2878, 1370 cm⁻¹ (-CH₃, CH₂), 1185 (C=S), 765(C-O-C ring). PMR: 7.24-7.65 (multiplet, 4H, Ar-H), 9.40 (singlet, 1H, NH), 4.86-4.38 (singlet, 4H, CH₂), 2.66 (quartet, 2H, CH₂), 1.12 (triplet, 3H, CH₃), 2.28(singlet, 3H, CH₃). Analysis. Calculated for C₁₄H₁₇N₅OS(303): C, 55.42; H, 5.65; N, 23.08; S, 10.57. Found: C, 55.41; H, 5.63; N, 23.06; S, 10.55.

1,3,4-oxadiazole-2(3H)-thione (4a-e): In a R.B.flask, the mixture of 5-((2-((ethylmethylamino) methyl)-1H-benzimidazol-1-yl) methyl)-1, 3, 4-oxadiazole-2(3H)-thione (3) (0.01mole) in THF (100ml), HCHO (0.01mole) and secondary amine (a-e) (0.12mole) was refluxed on water bath for 3-3.5 hrs. This mixture was concentrated, cooled and poured into ice-cold water. After air-dried, this product was recrystallized by n-hexane and gave 3-((dialkylamino) methyl)-5-((2-((ethyl (methyl) amino) methyl)-1H-benzimidazol-1-yl) methyl)-1, 3, 4-oxadiazole-2(3H) -thione (4a-e), which was obtained in 65-76% yield. The Yields, M.P and other analytical data of these compounds are presented in table-1

Biological Activities: Antibacterial screening: The antibacterial screening of all the compounds (4a-e) were studied for gram-positive (*Bacillus subtilis* and *Staphylococcus aureus*) and gram-negative (*klebsiella promioe* and *E.coli*) bacteria at a concentration of 50µg/ml by agar cup plate method. As a control, the methanol system was used. Tetracycline used as standard for comparison in similar conditions. The area of zone inhibition measured in mm. The antibacterial screening of all the compounds (4a-e) is shown in table-2.

Preparation of 3-((dialkylamino)methyl)-5-((2-((ethyl (methyl) amino)methyl)-1H-benzimidazol-1-yl) methyl) -

Table-1
Elemental and Analytical data of Compounds (4a-e)

Compd.	Molecular Formula (Mol.Wt.)	Yield %	M.P. °C	Elemental Analysis							
				%C		%H		%N		%S	
				Found	Calcd.	Found	Calcd.	Found	Calcd.	Found	Calcd.
4a	C ₁₇ H ₂₄ N ₆ OS (324)	67	197	56.62	56.64	6.69	6.71	23.29	23.31	8.88	8.90
4b	C ₁₈ H ₂₆ N ₆ OS (374)	76	186	57.70	57.73	6.98	7.00	22.43	22.44	8.55	8.56
4c	C ₁₉ H ₂₈ N ₆ OS (388)	74	187	58.71	58.74	7.25	7.26	21.61	21.63	8.23	8.25
4d	C ₂₃ H ₂₈ N ₆ OS (436)	69	195	63.25	63.28	6.43	6.46	19.24	19.25	7.32	7.34
4e	C ₂₇ H ₂₈ N ₆ OS (484)	65	182	66.91	66.92	5.80	5.82	17.32	17.34	6.61	6.62

Table-2
Antibacterial screening of Compounds (4a-e)

Compounds	Gram-positive		Gram-negative	
	<i>Bacillus subtilis</i>	<i>Staphylococcus aureus</i>	<i>Klebsiella promioe</i>	<i>E.coli</i>
4a	53	47	66	61
4b	52	49	65	60
4c	55	48	58	65
4d	63	56	69	70
4e	64	57	71	72
Tetracycline	68	60	77	80

Antifungal screening: The antifungal screening of all the compounds was studied in vitro at 1000 ppm concentration. Plant pathogenic organisms *Rhizopus nigrican*, *Nigrospora Sp* and *Aspergillus niger* were used. The antifungal activities of all the synthesized compounds (4a-e) were studied on each of these plant pathogenic strains on a PDA (potato dextrose agar) medium. This PDA medium is a mixture of potato 200g, dextrose 20g, agar 20g and water 1c. Old cultures of five days were employed. The compounds to be screen were suspended (1000ppm) in a PDA medium which autoclaved at 120°C for 15 min. at 15atm. pressure. After cooling the Petri plates these media were poured into it and the organisms were inoculated. Ketoconazole was used as a standard in same condition. After 5 days the percentage inhibition for fungi was calculated using the formula given below.

Percentage of inhibition = $100(X-Y) \div X$

Where, Area of colony in control plate = X. Area of colony in test plate = Y.

The fungicidal screening by compounds (4a-e) is shown in table-3.

Table-3
Antifungal screening of Compounds (4a-e)

Compounds	Zone of Inhibition at 1000 ppm (%)		
	<i>Rhizopus Nigrican</i>	<i>Nigrospora Sp.</i>	<i>Aspergillus Niger</i>
4a	58	63	62
4b	56	62	60
4c	62	61	59
4d	66	69	63
4e	69	67	67
Ketoconazole	78	75	72

Results and Discussion

The analytical data shows that the elemental compositions are consistence with predicted structure. (shown in Scheme-1). The Infra Red and PMR spectral data also support to the predicted structure. The structures assigned to 3-((dialkylamino)methyl)-5-((2-((ethyl(methyl)amino)methyl)-1H-benzoimidazol-1-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione (4a-e) were supported by the analytical data. Infra Red and PMR spectra showing an absorption bands at 1620-1648(C=N), 3020-3080cm⁻¹(C-H of Ar.), 2950, 2878, 1370cm⁻¹ (-CH₃,CH₂), 1185(C=S), 765(C-O-C ring). PMR: 7.24-7.65(multiplet, 4H,Ar-H), 4.86-4.38(singlet,4H,CH₂), 2.66(quartet,2H,CH₂), 1.12(triplet,3H,CH₃), 2.28(singlet,3H,CH₃), 3.82 (singlet,2H,CH₂), 4a; 2.17(singlet, 6H,CH₃), 4b; 2.26(singlet,3H,CH₃), 1.08(triplet,3H,CH₃), 2.67(quartet,2H,CH₂), 4c; 1.08(triplet,6H,CH₃), 2.67(quartet,4H,CH₂), 4d; 1.08(triplet,3H,CH₃), 2.67(quartet,2H,CH₂), 6.82-7.27(multiplet, 5H,Ar-H), 4e; 6.82-7.27 (multiplet,10H, Ar-H). The data of all compounds including C, H, N and S analysis are in table-1.

The antibacterial screenings of all synthesized compounds (4a-e) were studied for gram-positive (*Staphylococcus aureus* and *Bacillus subtilis*) and gram-negative (*E.coli* and *klebsiella promioe*) bacteria. Compounds 4d and 4e were more toxic for these bacteria, rest of the compounds found less or moderate active as a antibacterial agent than tetracycline. The activity is shown in table -2.

The fungicidal screenings of all synthesized compounds (4a-e) were studied in vitro Plant pathogenic organisms like *Nigrospora Sp*, *Rhizopus nigricum* and *Aspergillus Niger*. After 5 days the percentage inhibition for fungi was calculated. Compounds 4d and 4e were more active, other compounds show less or moderate active. The activity is displayed in table-3

Acknowledgements

We are thankful to K K Shah Jarodwala Maninagar Science College, Ahmedabad. Gujarat, INDIA. and Shri R K Parikh Arts and Science College, Petlad.Gujarat, INDIA for motivation, Support and help for research work.

Conclusion

The fused derivatives of novel heterocyclic compound (4a-e) were successfully synthesized. With the help of analytical and spectral data the structures of new compounds were established. The novel compounds were examined for their antibacterial and antifungal activities. Among all the synthesize compounds 4d and 4e are more active as antibacterial and antifungal agent.

References

1. Padmavathi V., Reddy G.S, Padmaia A., Kondaiah P., Shazia A., Synthesis, antimicrobial and cytotoxic activities of 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazoles, *Eur J Med Chem.*, **44(5)**, 2106-2112, (2008)
2. Karegoudar P., Parasa D.J., Ashok M., Mahalinga M., Poojary B. and Holla B.S., Synthesis, antimicrobial and anti-inflammatory activities of some 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 1,2,4-triazolo[3,4-b][1,3,4]thiadiazines bearing trichlorophenyl moiety, *Eur J Med Chem.*, **43(4)**, 808-815,(2008)
3. Acharya B.N. and Saraswat D., Pharmacophore based discovery of potential antimalarial agent targeting haem detoxification pathway, *Eur J Med Chem.*, **43(12)**, 2840-2852, (2008)
4. Ajay Kumar K., Jayaroopa P., Vasanth Kumar G., Comprehensive Review On The Chemistry Of 1,3,4-Oxadiazoles And Their Applications, *International Journal of ChemTech Research*, **4(4)**,1782-1791 (2012)
5. Naik T.A. and Chikhalia K.H., Studies On Synthesis Of Pyrimidine Derivatives And Their Pharmacological Evaluation, *E-journal of chemistry*, **4(1)**, 60-66 (2007)

6. Bhatia S. and Gupta M, 1, 3, 4-Oxadiazole as antimicrobial agents: An overview, *J. Chem. Pharm. Res.*, **3(3)**, 137-147(2011)
7. Ragavendran J.V., Sriram D., Patel S.K., Reddy I.V., Bharathwajan N., Stables J., Yogeewari P., Design and synthesis of anticonvulsants from a combined phthalimide–GABA–anilide and hydrazone pharmacophore, *Eur J Med Chem.*, **42(2)**, 146–151(2007)
8. Kaymakçioğlu K.B., Oruç E.E., Unsalan S., Kandemirli F., Shvets N., Rollas S., Anatholy D., Synthesis and characterization of novel hydrazide–hydrazones and the study of their structure–antituberculosis activity, *Eur. J. Med. Chem.*, **41(11)**, 1253-1261 (2006)
9. Küçükgülzel S.G., Kocatepe A., Clercq E. De, Sahin F., Güllüce M., Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide, *Eur. J. Med. Chem.*, **41(3)**, 353-359 (2006)
10. Jain S.K. and Nandan J., Synthesis and Biological Evaluation of 3, 5-Disubstituted-1,2,4-Oxadiazoles as Antihistaminic Agents *World Journal of Pharmacy and Pharmaceutical Sciences*, **3(7)**, 762-773 (2014)
11. Harish K., Sadique A.J., Suroor A.K. and Mohammad A., Synthesis And Biological Evaluation Of 3, 5-Disubstituted-1,2,4-Oxadiazoles As Antihistaminic Agents, *Eur J Med Chem.*, **43(12)**, 2688-2698 (2008)
12. Karabasanagouda T., Adhikari A.V. and Shetty N.S., Synthesis and Antimicrobial Activities of Some novel 1,3,4-Oxadiazoles Carrying Alkylthio and Alkylsulphonyl phenoxy Moieties, *Phosp Sulf and Silicon*, **182(12)**, 2925-2941 (2007)
13. Fang L., Luo X.O., Song B.A., Bhadury P.S., Song Y., Jin L.H., Weixue X. and Hu D.Y., Synthesis and antifungal activity of novel sulfoxide derivatives containing trimethoxyphenyl substituted 1,3,4-thiadiazole and 1,3,4-oxadiazole moiety, *Bioorg Med Chem.*, **16(7)**, 3632-3640 (2008)
14. Zicane D., Teter Z., Mierina I., Turks M., Ravina I. and Leonciks A., Synthesis of quinazolinone-1,3,4 oxadiazole conjugates and studies of their antibacterial and antioxidant activity *Journal of Chemical and Pharmaceutical Research*, **6(4)**, 1153-1158 (2014)
15. Somashekhar M., Sonnad B., Tare B., Heralagi R.V. and Lokapure S., Synthesis and Antimicrobial activity of 5[4(morpholin-4-yl) phenyl]1,3,4 Oxadiazole 2-yl Sulphonyl acetohydrazide Derivatives *International Journal of Medicine and Pharmaceutical Research*, **2(2)**, 560-569 (2014)
16. Harish K.P., Mohana K.N., Mallesha L. and Veeresh B., Synthesis and in vivo anticonvulsant activity of 2-methyl-2-[3-(5-piperazin-1-yl-[1,3,4]oxadiazol-2-yl)-phenyl]-propionitrile derivatives, *Arch. Pharm. Chem. Life Sci.*, **347(4)**, 256-267, (2014)
17. Sun J., Zhu H., Yang Z. and Zhu H., Synthesis, molecular modeling and biological evaluation of 2-aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3H)-thione quinolone derivatives as novel anticancer agent, *Eur. J. Med. Chem.*, **60**, 23-28, (2013)
18. Rane R.A., Bangalore P., Borhade S.D. and Khandare P. K., Synthesis and evaluation of novel 4-nitropyrrole-based 1,3,4-oxadiazole derivatives as antimicrobial and anti-tubercular agents, *Eur. J. Med. Chem.*, **70**, 49-58, (2013)
19. Clitherow J.W., Beswick P., Irving W.J., Scopes D.I.C., Barnes J.C., Clapham J., Brown J.D., Evans D.J. and Hayes A.G., Novel 1, 2, 4-oxadiazoles as potent and selective histamine H3 receptor antagonists, *Bioorg. Med. Chem. Lett.*, **6(7)**, 833-838 (1996)
20. Grabmann S., Sadek B., Ligneau X., Elz S., Ganellin C.R., Arrang J.M., Schwartz J.C., Stark H. and Schunack W., Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H(3)-receptor antagonists, *Eur. J. Pharm. Sci.*, **15(4)**, 367-378 (2002)
21. Shah H.J. and Chaudhari J.A., Synthesis, characterization and biological studies of some novel benzimidazole derivatives, *J. Chem. Pharm. Res.*, **6(7)**, 1890-1894 (2014)
22. Shah H.J. and Chaudhari J.A., Studies of Novel Heterocyclic Compounds, *Der Pharma Chemica*, **6(6)**, 79-83 (2014)
23. Lingala S., Nerella R. and Sambasiva Rao K.R.S., Synthesis, Antimicrobial And Anthelmintic Activity Of Some Novel Benzimidazole Derivatives, *International Journal of Pharmaceutical Sciences Review and Research.*, **10(2)**, 100-105 (2011)